<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table4" position="float"><object-id pub-id-type="doi">10.7554/eLife.33478.010</object-id><label>Table 4.</label><caption><title>Sub-group analyses of the primary efficacy outcome in the intention-to-treat population.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th valign="top">Placebo (events/n (risk%))</th><th valign="top">Aspirin 81 mg (events/n (risk%))</th><th valign="top">Aspirin 1000 mg (events/n (risk%))</th><th valign="top">P-value comparison</th><th valign="top">P-heterogeneity</th></tr></thead><tbody><tr><td valign="top">Diagnostic criteria <break/>&#8195;- Definite <break/>&#8195;- Probable/Possible</td><td valign="top"><break/>11/32 (34.4%) <break/>0/6 (0%)</td><td valign="top"><break/>4/27 (14.8%) <break/>3/8 (37.5%)</td><td valign="top"><break/>3/28 (10.7%) <break/>3/10 (30.0)</td><td valign="top"><break/>0.06 <break/>0.30</td><td valign="top"><break/>0.01</td></tr><tr><td valign="top">MRC Grade <break/>&#8195;- I <break/>&#8195;- II <break/>&#8195;- III</td><td valign="top"><break/>4/16 (25.0%) <break/>4/17 (23.5%) <break/>3/5 (60.0%)</td><td valign="top"><break/>1/15 (6.7%) <break/>4/17 (23.5%) <break/>3/4 (75.0%)</td><td valign="top"><break/>1/14 (7.1%) <break/>4/19 (21.1%) <break/>1/5 (20.0%)</td><td valign="top"><break/>0.33 <break/>1.00 <break/>0.42</td><td valign="top"><break/>0.44</td></tr><tr><td valign="top">Previous tuberculosis treatment <break/>&#8195;- Yes <break/>&#8195;- No</td><td valign="top"><break/>1/2 (50.0%) <break/>10/36 (27.8%)</td><td valign="top"><break/>1/1 (100%) <break/>7/35 (20.0%)</td><td valign="top"><break/>0/1 (0%) <break/>6/37 (16.2%)</td><td valign="top"><break/>1.00 <break/>0.51</td><td valign="top"><break/>0.28</td></tr><tr><td valign="top">Drug susceptibility* <break/>&#8195;- MDR-TB <break/>&#8195;- Rifampicin mono-resistance <break/>&#8195;- Isoniazid resistance (with or without streptomycin resistance) <break/>&#8195;- No or other resistance</td><td valign="top"><break/>0/0 (0%) <break/>0/1 (0%) <break/>3/6 (50.0%) <break/><break/>5/10 (50.0%)</td><td valign="top"><break/>1/1 (100%) <break/>0/0 (0%) <break/>1/1 (100%) <break/><break/>1/7 (14%)</td><td valign="top"><break/>0/0 (0%) <break/>0/0 (0%) <break/>1/2 (50.0%) <break/><break/>1/12 (8%)</td><td valign="top"><break/>1.00 <break/> <break/> <break/><break/>0.09</td><td valign="top"><break/>0.17</td></tr><tr><td valign="top">LTA4H genotype&#8224; <break/>&#8195;- CC <break/>&#8195;- CT <break/>&#8195;- TT</td><td valign="top"><break/>3/18 (16.7%) <break/>7/16 (43.8%) <break/>1/4 (25.0%)</td><td valign="top"><break/>4/13 (30.8%) <break/>3/16 (18.8%) <break/>1/6 (16.7%)</td><td valign="top"><break/>0/16 (0%) <break/>5/19 (26.3%) <break/>0/1 (0%)</td><td valign="top"><break/>0.05 <break/>0.30 <break/>1</td><td valign="top"><break/>0.13</td></tr></tbody></table><table-wrap-foot><fn><p>*4 participants not genotyped. P-value for the heterogeneity was obtained from likelihood ratio tests for an interaction term between treatment and the grouping variable in a logistic regression model.</p><p><sup>&#8224;</sup>Outcomes unavailable in two participants in the placebo group with DST available (one lost to follow-up at day 57 and one did not have MRI information at day 60).</p></fn></table-wrap-foot></table-wrap>